As Affy Readies 100K SNP Array for Market, Competition Says Ho-Hum | GenomeWeb

This fall, Affymetrix will begin rolling out its 100K SNP array to a small number of academic labs and drug makers. The product, which is slated for general launch in the second half of next year, is intended to become a linchpin in the firm’s plan to enter the SNP-analysis market.

In the short term, the move will place Affy, the world leader in DNA chip sales, at the back of a queue of highly competitive platform companies intent on holding onto a finite customer base.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.